【欢迎正在创业以及寻求融资的公司和寻找合适项目的投资机构联系我们，大家可以一起合作、交流、资源对接、互通有无或者创造更多无限可能，为保证真实性和效率，联系我们时请备注公司+姓名，无关人员请不要添加】 猛兽财经获悉，美国生物技术研发 ...

路透社11月18日消息，知情人士称，为科学家和医药研究机构开发软件工具的初创企业Benchling已向监管机构秘密提交在纽交所上市的文件。 据悉，这家总部位于加州旧金山的公司在今年早些时候的一轮融资中估值为40亿美元，其目标是在2022年初以更高的估值上市。

Email and a smarter notebook might be enough for handling communication for projects or experiments inside a team in a lab in some university basement. But when you have around 200 scientists working ...

In a field where the laboratory notebook is still considered the state of the art, it’s no wonder a company like Benchling, which provides software for managing life sciences research, was able to nab ...

The first command center for scientific AI, bringing agents and models to every scientist SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ -- Benchling AI launches today, giving scientists a command center to ...

Benchling AI debuts alongside major new capabilities for antibody discovery, automated data analysis, and development BOSTON, Oct. 14, 2025 /PRNewswire/ -- Benchling today unveiled major new ...

Ten years ago, Sajith Wickramasekara dropped out of the Computer Science program at MIT to build something new: a software company that helps life science researchers better organize their lab work.

SAN FRANCISCO and BOSTON, May 7, 2025 /CNW/ -- Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration with Moderna. What began with Benchling supporting ...

Investors are eager for the Benchling IPO. The company made headlines when it confidentially filed with the SEC to go public. Biotechnology is rewriting life as we know it. Our customers, spanning ...

SAN FRANCISCO--(BUSINESS WIRE)--Today Benchling, the data management and collaboration platform built to advance life sciences research, announced it has closed $14.5M in Series B funding. The round ...

On Thursday, San Francisco-based R&D cloud software company Benchling announced that it has acquired Belfast-based Ovewatch Research, a software company for customers working on preclinical biopharma ...